Exact Sciences Corp (EXAS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Exact Sciences Corp (EXAS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10008
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer. The company is also working on the development of additional tests for other types of cancers and identified proprietary methylation markers for several major cancers. It operates laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.

Exact Sciences Corp (EXAS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Exact Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Exact Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 9
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Biomatrica Raises USD18.1 Million in Financing 11
Partnerships 12
Microbiologics Enters into Licensing Agreement with Biomatrica 12
Licensing Agreements 13
Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 13
Equity Offering 14
Exact Sciences Raises USD245 Million in Public Offering of Shares 14
Exact Sciences Prices Public Offering of Shares for USD178.5 Million 16
Exact Sciences Completes Public Offering Of Shares For US$146.6 Million 17
Exact Sciences Completes Public Offering Of Shares For US$78 Million 19
Exact Sciences Completes Public Offering of Common Stock For US$62 Million 20
Debt Offering 21
Exact Sciences Prices Public Offering of 1% Convertible Senior Notes Due 2025 for USD190 Million 21
Exact Sciences Raises USD690 Million in Public Offering of Senior Notes Due 2025 22
Exact Sciences Corp – Key Competitors 23
Exact Sciences Corp – Key Employees 24
Exact Sciences Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Aug 14, 2018: University Research Park Breaks Ground on Corporate Headquarters Building for Exact Sciences 27
Financial Announcements 28
Oct 30, 2018: Exact Sciences announces third quarter 2018 financial results 28
Jan 07, 2018: Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017 29
Jul 25, 2017: Cologuard revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 30
Feb 21, 2017: Exact Sciences reports lower Q4 net loss, provides outlook for 2017 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Exact Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Exact Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Exact Sciences Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Exact Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 9
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Biomatrica Raises USD18.1 Million in Financing 11
Microbiologics Enters into Licensing Agreement with Biomatrica 12
Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 13
Exact Sciences Raises USD245 Million in Public Offering of Shares 14
Exact Sciences Prices Public Offering of Shares for USD178.5 Million 16
Exact Sciences Completes Public Offering Of Shares For US$146.6 Million 17
Exact Sciences Completes Public Offering Of Shares For US$78 Million 19
Exact Sciences Completes Public Offering of Common Stock For US$62 Million 20
Exact Sciences Prices Public Offering of 1% Convertible Senior Notes Due 2025 for USD190 Million 21
Exact Sciences Raises USD690 Million in Public Offering of Senior Notes Due 2025 22
Exact Sciences Corp, Key Competitors 23
Exact Sciences Corp, Key Employees 24
Exact Sciences Corp, Subsidiaries 26

List of Figures
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Exact Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Exact Sciences Corp (EXAS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sherritt International Corp (S):石油・ガス:M&Aディール及び事業提携情報
    Summary Sherritt International Corp (Sherritt) is a natural resources company. It carries out mining and refining activities for the production of nickel and cobalt from lateritic ores with ownership stake in Moa Joint Venture and Ambatovy Joint Venture. The company also explores, develops and produ …
  • Heathrow Airport Holdings Limited
    Heathrow Airport Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Heathrow Airport Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Wausau Paper Corporation:企業の戦略・SWOT・財務情報
    Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • China Development Bank
    China Development Bank - Strategy, SWOT and Corporate Finance Report Summary China Development Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Dycom Industries Inc (DY):企業の財務・戦略的SWOT分析
    Summary Dycom Industries Inc (Dycom Industries) is a technology company that provides contracting services. The company offers services to the telecommunications and infrastructure industries. It provides contracting services such as construction, locating, engineering, fulfilment, programs manageme …
  • The Capital Group Companies, Inc.:企業の戦略・SWOT・財務情報
    The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • WEC Energy Group Inc:企業の発電所・SWOT分析2018
    WEC Energy Group Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • RPC Group PLC:企業のM&A・事業提携・投資動向
    RPC Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's RPC Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Universal Forest Products, Inc.:戦略・SWOT・企業財務分析
    Universal Forest Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Universal Forest Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Hexion Inc.:企業の戦略・SWOT・財務情報
    Hexion Inc. - Strategy, SWOT and Corporate Finance Report Summary Hexion Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Sihuan Pharmaceutical Holdings Group Ltd (460):企業の財務・戦略的SWOT分析
    Summary Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures and markets prescription drugs. The company offers products in the therapeutic areas of cardio-cerebral vascular system, central nervous system, metabolism, oncology and a …
  • OmniComm Systems Inc (OMCM):医療機器:M&Aディール及び事業提携情報
    Summary OmniComm Systems Inc (OmniComm) is a provider of electronic data capture and eClinical software and services. It provides web-based applications to pharmaceutical, biotech and medical device companies. The company’s solutions allow clinical trial sponsors and investigative sites to securely …
  • Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析
    Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Instrumentation Laboratory Company-医療機器分野:企業M&A・提携分析
    Summary Instrumentation Laboratory Company (IL), a subsidiary of Werfen Life Group, is a medical device company with focus on in vitro diagnostics (IVD) devices. The company develops, manufactures, and distributes IVD instruments, related reagents and controls for hospitals and clinical laboratories …
  • Coca-Cola Icecek A.S.:戦略・SWOT・企業財務分析
    Coca-Cola Icecek A.S. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Icecek A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sterling Bank Plc
    Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Lam Research Corp (LRCX):企業の財務・戦略的SWOT分析
    Lam Research Corp (LRCX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Eco (Atlantic) Oil & Gas Ltd (EOG):企業の財務・戦略的SWOT分析
    Summary Eco (Atlantic) Oil & Gas Ltd (Eco) is an oil and gas exploration and development company. The company’s business activities include acquisition, identification, and development of upstream petroleum projects across Africa. The company's projects include cooper license-PEL 030, Sharon license …
  • Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析
    Summary Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes apealea (paclical), currently at registration and approval stage, for treating …
  • Ergomed Plc (ERGO):企業の財務・戦略的SWOT分析
    Summary Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd, is a drug development and clinical research services provider. The company provides various services such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and other …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆